Mereo BioPharma (MREO) Intangibles (2017 - 2026)
Mereo BioPharma (MREO) posted quarterly Intangibles of $381000.0 for Q1 2026, down 31.23% year-over-year from $554000.0 in Q1 2025, and down 26.16% quarter-over-quarter from $516000.0 in Q4 2025.
Mereo BioPharma (MREO) Intangibles (2017 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Intangibles for 10 consecutive years, with $381000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Intangibles fell 31.23% year-over-year to $381000.0; the TTM figure through Mar 2026 stood at $381000.0 (down 31.23% YoY), while the FY2025 annual figure was $516000.0, down 19.75% from the prior year.
- Intangibles declined to $381000.0 in Q1 2026 per MREO's latest filing, from $516000.0 in the prior quarter.
- Across five years, Intangibles topped out at $31.1 million in Q2 2023 and bottomed at $381000.0 in Q1 2026.
- Historically, Intangibles has averaged $7.4 million across 5 years, with a median of $799000.0 in 2024.
- Annual changes were most pronounced in 2023 — Intangibles grew 2.37% — and 2024, when it plunged 97.21%.
- Mereo BioPharma's Intangibles stood at $28.3 million in 2022, then tumbled by 96.15% to $1.1 million in 2023, then slumped by 40.96% to $643000.0 in 2024, then declined by 19.75% to $516000.0 in 2025, then retreated by 26.16% to $381000.0 in 2026.
- Business Quant data shows MREO's Intangibles at $381000.0 in Q1 2026, $516000.0 in Q4 2025, and $643000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Mereo BioPharma | 47.39 Mn | 47.39 Mn | - | 256,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 256,000.00 |
| Mar 31, 2026 | 381,000.00 |
| Dec 31, 2025 | 516,000.00 |
| Sep 30, 2025 | 643,000.00 |
| Jun 30, 2025 | 470,000.00 |
| Mar 31, 2025 | 554,000.00 |
| Dec 31, 2024 | 643,000.00 |
| Sep 30, 2024 | 799,000.00 |
| Jun 30, 2024 | 866,000.00 |
| Mar 31, 2024 | 972,000.00 |
| Dec 31, 2023 | 1.09 Mn |
| Jun 30, 2023 | 31.09 Mn |
| Dec 31, 2022 | 28.29 Mn |
| Jun 30, 2022 | 30.37 Mn |
| Dec 31, 2021 | 33.11 Mn |
| Jun 30, 2021 | 31.02 Mn |
| Dec 31, 2020 | 43.58 Mn |
| Jun 30, 2020 | 39.58 Mn |
| Dec 31, 2019 | 57.16 Mn |
| Jun 30, 2019 | 58.09 Mn |